Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic and is in charge of the committee that flagged a rare but severe side effect involving Syforve, a newly approved drug from Apellis (APLS), failed to report consulting fees and stock ownership in rival Iveric Bio (ISEE) to the American Society of Retinal Specialists, StatNews’ Adam Feuerstein reports. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving the Apellis drug, the report says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
- Apellis price target lowered to $82 from $100 at H.C. Wainwright
- Apellis price target lowered to $80 from $106 at Citi
- Apellis price target lowered to $40 from $86 at Wedbush
- Survey sees doctors cautious not bearish on Appelis’ Syfovre, says Baird